Show simple item record

dc.contributor.authorNaseri, N
dc.contributor.authorAjorlou, E
dc.contributor.authorAsghari, F
dc.contributor.authorPilehvar-Soltanahmadi, Y
dc.date.accessioned2018-08-26T07:12:39Z
dc.date.available2018-08-26T07:12:39Z
dc.date.issued2018
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/44769
dc.description.abstractDespite the great value of current exogenous contrast agents for providing main diagnostic information, they still have certain drawbacks such as short blood half life, nonspecific biodistribution, fast clearance, slight renal toxicity and poor contrast in fat patients. Nanoparticles (NPs) are used as novel contrast agents that represent a promising strategy for the non invasive diagnosis. As a platform, nanoparticulates are compatible for developing targeted contrast agents. Advances in nanotechnology will provide enhanced sensitivity and specificity for tumor imaging enabling earlier detection of metastases. This article focuses on fundamental issue such as biological interactions, clearance routes, coating of NPs and presents a wide discussion about most recent category of NPs that are used as contrast agents and the benefits/concerns issues associated with their use in clinical procedures.
dc.language.isoEnglish
dc.relation.ispartofARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
dc.subjectContrast agents
dc.subjectnanoparticles
dc.subjectbiological interactions
dc.subjectclearance routes
dc.subjectcoating
dc.titleAn update on nanoparticle-based contrast agents in medical imaging
dc.typeArticle
dc.citation.volume46
dc.citation.issue6
dc.citation.spage1111
dc.citation.epage1121
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.1080/21691401.2017.1379014


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record